IPCA Laboratories Limited (IPCALAB) AI Stock Analysis

• Market Cap: ₹326.29B
• Dividend Yield: 0.31%
• Average Volume (3M): 6.78K
• Price to Earnings (P/E): 41.9
• Beta (1Y): 0.59
• Revenue Growth: 11.49%
• EPS Growth: 35.00%
• Country: IN
• Employees: 17,335
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 9.19
• Shares Outstanding: 253,659,230
• 10 Day Avg. Volume: 6,645
• 30 Day Avg. Volume: 6,776
• PEG Ratio: 1.38
• Price to Book (P/B): 5.08
• Price to Sales (P/S): 3.95
• P/FCF Ratio: 70.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: ₹1,405.00 ▲(9.02% Upside)

IPCA Laboratories' overall stock score reflects strong financial performance with robust revenue growth and a solid balance sheet. However, technical indicators suggest a bearish trend, and the high P/E ratio indicates potential overvaluation. The lack of earnings call and corporate events data limits additional insights.

IPCA Laboratories Limited Business Overview & Revenue Model

Company Description

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

How the Company Makes Money

IPCA Laboratories generates revenue primarily through the sale of pharmaceutical formulations and APIs. The company has a strong focus on generic drugs, which are sold at competitive prices to healthcare providers and pharmacies. Key revenue streams include domestic sales, which contribute significantly to the total revenue, and exports to over 100 countries, including developed markets like the U.S. and Europe. Additionally, IPCALAB has established partnerships and collaborations with various healthcare organizations, enhancing its distribution network and expanding its market reach. The company also benefits from investments in research and development, leading to the introduction of new products that align with market demands and regulatory standards.

IPCA Laboratories Limited Financial Statement Overview

Summary

IPCA Laboratories shows strong revenue growth and a solid balance sheet with a healthy equity ratio. However, fluctuations in net profit margin and inconsistent free cash flow growth suggest areas for improvement in operational efficiency and profit margins.

Income Statement

IPCA Laboratories has demonstrated consistent revenue growth over recent years, with a notable increase from 45,587 million in 2020 to 89,395.9 million in 2025. The gross profit margin is strong, averaging over 40% annually, indicating effective cost management. However, the net profit margin has seen fluctuations, primarily due to varying EBIT margins and changes in operating expenses. The company needs to focus on enhancing its EBIT margin to maintain stable profitability.

Balance Sheet

The balance sheet of IPCA Laboratories shows a healthy equity ratio, consistently above 50%, signifying solid financial stability and a strong capital structure. The debt-to-equity ratio is moderate, reflecting controlled leverage, although it increased slightly in recent years. Return on equity has been somewhat volatile, influenced by changes in net income, suggesting potential areas for operational improvements.

Cash Flow

IPCA Laboratories exhibits sound cash flow management, with positive operating cash flow and free cash flow over the years. However, the free cash flow growth rate has been inconsistent, pointing to fluctuations in capital expenditures and operating efficiencies. The operating cash flow to net income ratio is healthy, indicating good conversion of earnings into cash flows.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	91.57B	89.41B	77.06B	62.48B	58.30B	54.21B
Gross Profit	60.28B	58.60B	48.58B	37.25B	36.23B	35.24B
EBITDA	16.87B	16.67B	12.64B	9.46B	12.75B	15.07B
Net Income	7.79B	7.38B	5.47B	4.71B	8.84B	11.40B
Balance Sheet
Total Assets	0.00	117.61B	111.01B	86.26B	76.24B	60.68B
Cash, Cash Equivalents and Short-Term Investments	11.05B	11.08B	8.45B	21.79B	13.59B	7.58B
Total Debt	0.00	13.63B	14.38B	14.81B	8.07B	2.65B
Total Liabilities	-83.88B	33.72B	33.74B	27.11B	20.82B	13.52B
Stockholders Equity	83.88B	69.48B	63.32B	58.42B	54.92B	47.02B
Cash Flow
Free Cash Flow	0.00	5.00B	5.33B	3.11B	3.77B	7.29B
Operating Cash Flow	0.00	12.75B	9.45B	8.06B	8.56B	10.90B
Investing Cash Flow	0.00	-8.94B	-12.92B	-7.25B	-8.55B	-5.21B
Financing Cash Flow	0.00	-2.13B	-5.53B	5.07B	4.27B	-3.06B

IPCA Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1288.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IPCALAB, the sentiment is Negative. The current price of 1288.7 is below the 20-day moving average (MA) of 1305.29, below the 50-day MA of 1336.64, and below the 200-day MA of 1401.78, indicating a bearish trend. The MACD of -17.51 indicates Negative momentum. The RSI at 43.51 is Neutral, neither overbought nor oversold. The STOCH value of 50.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:IPCALAB.

IPCA Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AJANTPHARM	―	₹304.66B	32.75	―	2.26%	10.92%	9.76%
GLAND	―	₹318.91B	41.40	―	0.94%	-2.34%	6.64%
LAURUSLABS	―	₹485.71B	95.39	―	0.16%	25.83%	421.20%
IPCALAB	―	₹326.29B	41.91	―	0.31%	11.49%	35.00%
BIOCON	―	₹498.48B	114.16	―	0.13%	6.80%	-75.66%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLENMARK	―	₹522.88B	69.69	―	0.13%	10.99%	―

IPCA Laboratories Limited Corporate Events

IPCA Laboratories Expands with New German Subsidiary

IPCA Laboratories Limited has announced the incorporation of a wholly owned subsidiary, Ipca Pharmaceuticals GmbH, in Germany. This strategic move aims to enhance the company’s operations by holding product registrations and distributing generic formulations in the German market, potentially strengthening its position in the European pharmaceutical industry.

IPCA Laboratories Announces Trading Window Closure

IPCA Laboratories Limited has announced the closure of its trading window in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. This closure will be effective from October 1, 2025, and will last until 48 hours after the company announces its unaudited financial results for the second quarter and half-year ending September 30, 2025. The date for the board meeting to consider these financial results will be communicated to the stock exchanges in due course, indicating a period of restricted trading activity for insiders.